Yes, for many women.

The perimenopause is a recognized window of vulnerability for depressive symptoms and diagnosed depressive episodes. In women with no depression history, entering the transition roughly quadrupled the odds of clinically significant depressive symptoms and multiplied by 2.5 the odds of a diagnosed depressive disorder in one cohort, and about doubled the risk of significant depressive symptoms in another. That said, most midlife women who experience a major depressive episode during perimenopause have had a prior episode of depression, so both a genuine first-onset window and a strong history effect are real and worth naming together. Risk tends to peak before the final period and fall afterward.

What to know about this answer

The two positions are not actually contradictory: relative risk of a first depressive episode genuinely rises during the transition, while the absolute case mix of midlife depression is dominated by women who have had a prior episode. Both matter clinically.

What the research shows, and which source each finding rests on

The perimenopause is a recognized 'window of vulnerability' for both depressive symptoms and major depressive episodes, the consensus position of the 2018 joint guidelines

A[1]

In women with no history of depression, entering the menopause transition roughly quadrupled the odds of clinically significant depressive symptoms (OR 4.29, 95 percent CI 2.39-7.72) and multiplied by 2.5 the odds of a diagnosed depressive disorder (OR 2.50, 95 percent CI 1.25-5.02), compared with the same women premenopausally

C[2]

Women with no lifetime depression history who entered perimenopause were about twice as likely to develop significant depressive symptoms as those who stayed premenopausal, with somewhat greater risk in those with vasomotor symptoms

C[3]

In a 14-year within-woman analysis, depressive symptom risk was higher in the years before the final menstrual period and lower after it; a prior depression history multiplied risk roughly 13-fold overall

C[4]

Where the real disagreement is

Each position is shown with its own sources. A position listed here is not necessarily the accepted view.

Genuine first-onset window

Freeman and colleagues' Penn Ovarian Aging cohort, and Cohen and colleagues' Harvard Study of Moods and Cycles

Women with no depression history entering the transition show two-to-four-fold increased risk of significant depressive symptoms and about two-and-a-half-fold risk of a diagnosed depressive disorder, with hormone-flux mechanisms demonstrated experimentally in other work.

C[2]C[3]

Mostly recurrence

The 2018 consensus guideline authors

Most midlife women who experience a major depressive episode during perimenopause have experienced a prior episode of depression, and a prior depression history multiplies risk roughly 13-fold, making history the dominant factor in the overall case mix.

A[1]C[4]

What would settle it: Cohorts using structured diagnostic interviews, not just symptom scales, large enough to estimate true first-onset incidence by precise transition stage.

What is really going on here

  1. Was my depression history taken before my mood symptoms were attributed to hormones, or dismissed as stress? History of depression is the single strongest predictor of a midlife major depressive episode.
  2. Am I being offered an antidepressant as a reflex, or after an actual evaluation? The right question is not 'antidepressant or hormones' but whether I was staged, screened, and offered the full menu of options.

Questions for your doctor

  1. Have I been screened for depression using a validated tool, not just asked how I'm feeling?
  2. What is my personal depression history, including postpartum or premenstrual mood sensitivity?
  3. Where am I in the transition, and could that explain the timing of these symptoms?
  4. What are all my treatment options, including psychotherapy and, if appropriate, hormone therapy, not just an antidepressant?

Questions with no answer yet

Do the same markers that predict depressed mood in one cohort, such as estradiol variability rather than absolute level, actually distinguish who develops a first depressive episode from who has a recurrence?

Not directly studied yet

No research does not mean it does not work, and it does not mean it works. It means nobody has tested it yet.

What is known: Within-woman hormone variability, more than absolute level, was independently associated with depressed mood in one cohort, but no study has tested whether that same variability marker distinguishes genuine first-onset cases from recurrence in women with a prior history.

What would test it: A cohort measuring hormone variability alongside detailed depression history, structured diagnostic interviews, and new-onset versus recurrent episode classification.

If depression screening at menopause used structured diagnostic interviews instead of symptom scales, would the first-onset window turn out to be larger or smaller than currently estimated?

Not directly studied yet

No research does not mean it does not work, and it does not mean it works. It means nobody has tested it yet.

What is known: The guideline literature states directly that what would settle the remaining edge of this debate is cohorts using structured diagnostic interviews, not just symptom scales, large enough to estimate true first-onset incidence by precise transition stage. This has not been done.

What would test it: A large cohort using structured clinical interviews, not just symptom questionnaires, staged by standard menopause-transition criteria.

Is the roughly thirteen-fold risk multiplier from a prior depression history a fixed biological vulnerability, or does it partly reflect that women with a known history get watched more closely and diagnosed sooner?

Not directly studied yet

No research does not mean it does not work, and it does not mean it works. It means nobody has tested it yet.

What is known: A fourteen-year within-woman analysis reports the history effect as a large multiplier without addressing whether surveillance or detection bias contributes to its size.

What would test it: A study comparing depression detection rates and thresholds between women with and without a known history, to separate true risk from detection bias.

Sources

  1. 1.Guidelines for the evaluation and treatment of perimenopausal depression: summary and recommendations.Maki PM, Kornstein SG, Joffe H et al., Menopause 2018 · Systematic review or guideline
  2. 2.Associations of hormones and menopausal status with depressed mood in women with no history of depression.Freeman EW et al., Arch Gen Psychiatry 2006 · Observational study
  3. 3.Risk for new onset of depression during the menopausal transition: the Harvard study of moods and cycles.Cohen LS et al., Arch Gen Psychiatry 2006 · Observational study
  4. 4.Longitudinal pattern of depressive symptoms around natural menopause.Freeman EW et al., JAMA Psychiatry 2014 · Observational study

The letter grades the type of study behind a claim, not the answer itself.

This page is general information based on published research and public sources. It is not medical advice and not a personal assessment, and it does not replace a conversation with your doctor. Peritale is a wellness product, not a medical device, and is not intended to diagnose, treat, cure or prevent any disease. For any medical question, speak with a licensed clinician.

You are not imagining it

In about seven minutes on your phone, Peritale reads five signal systems and maps your symptoms, so you can see that what you feel is real, follow your hormonal transition over time, and walk into your doctor ready to ask for the care you deserve. Your first check is free, no credit card.

Start Free Mapping

Related questions

Related guides